Speakers 2011
-
Hepatitis C: towards a personalised management (chairman)
-
Non invasive markers of fibrosis : an easy access to treatment? (chairman)
Presentation
-
ALBERTI Alfredo
Italy
-
Impact of SVR on the long term outcome of the liver disease
-
Individualised approach to managing naive patients (chairman)
Presentation
-
-
Advantages of new generation DAAs ?
-
State of the Art lecture (chairman)
Presentation
-
BELGHITI Jacques
France
-
Liver transplantation: expanding criteria?
Presentation
-
BELHADJ BRIK Najet
Tunisia
-
French speaking luncheon: Comment prendre en charge les patients atteints d’hépatite C?
Presentation
-
-
French speaking luncheon: Comment optimiser la prise en charge des patients AgHBe négatif?
Presentation
-
BERENGUER Marina
Spain
-
Management of difficult to treat patients
Presentation
-
-
Active or inactive carrier: where is the frontier? (chairman)
Presentation
-
-
HBeAg-negative chronic hepatitis B (chairman)
Presentation
-
-
New combinations (chairman)
Presentation
-
-
Management of difficult to treat patients
Presentation
-
BRUNETTO Maurizia
Italy
-
HBsAg: cvirologic significance
-
The role of HBsAg quantifi cation vs HBV DNA in clinical management of Hepatitis B
Presentation
-
-
How to manage patients with resistant HBV
Presentation
-
CARDOSO Ana Carolina
Brazil
-
Non invasive markers of fibrosis : an easy access to treatment?
Presentation
-
-
Serum markers or Fibroscan vs liver biopsy?
Presentation
-
-
The Zurich HCC liver transplantation consensus conference
-
Hepatocellular carcinoma. Asian vs European experience
Presentation
-
-
How I manage my patients with hepatocellular carcinoma
-
Hepatocellular carcinoma. Asian vs European experience (chairman)
Presentation
-
COUZIGOU Patrice
France
-
French speaking luncheon: Comment prendre en charge les patients atteints d’hépatite C?
Presentation
-
-
Genotype 2 and 3 patients
-
Management of difficult to treat patients (chairman)
Presentation
-
-
Non invasive markers of fibrosis : an easy access to treatment?
Presentation
-
-
French speaking luncheon: Comment prendre en charge les patients atteints d’hépatite C? (chairman)
Presentation
-
DUSHEIKO Geoffrey
UK
-
HBeAg-negative chronic hepatitis B (chairman)
Presentation
-
-
Individualised approach to managing naive patients
Presentation
-
-
Hepatitis B: towards a personalised management (chairman)
Presentation
-
-
Optimising therapy in real life (chairman)
Presentation
-
FLISIAK Robert
Poland
-
Triple therapy: who and how?
Presentation
-
-
Experienced patients
Presentation
-
GANE Edward
New Zealand)
-
Are interferons really necessary?
Presentation
-
HADZIYANNIS Stephanos
Greece
-
Milestones and perspectives in hepatitis B
Presentation
-
-
Triple therapy: who and how?
Presentation
-
JANSSEN Harry
The Netherlands
-
Why do I treat my patient with pegylated interferon?
Presentation
-
-
HBeAg-positive chronic hepatitis B (chairman)
Presentation
-
KAMAL Sanaa
Egypt
-
Genotype 4 patients
Presentation
-
-
Hepatitis B: towards a personalised management (chairman)
Presentation
-
-
Why do I treat my patient with pegylated interferon?
Presentation
-
-
HBeAg-positive chronic hepatitis B (chairman)
-
The role of HBsAg quantifi cation vs HBV DNA in clinical management of Hepatitis B (chairman)
Presentation
-
LEUNG Nancy
Hong Kong
-
Why do I treat my patient with a nucleos(t)ide analogue?
-
Active or inactive carrier: where is the frontier?
Presentation
-
-
Hepatitis C: towards a personalised management (chairman)
Presentation
-
-
Optimising therapy in real life (chairman)
Presentation
-
LIAW Yun-Fan
Taiwan
-
Impact of therapy on the long term outcome of liver disease
Presentation
-
LLOVET Josep
Spain
-
Local regional approach
Presentation
-
MANNS Michael
Germany
-
New combinations (chairman)
Presentation
-
-
Introduction : Viral Hepatitis in 2011
-
Award ceremony (chairman)
-
Conclusion and perspectives
Presentation
-
MATHURIN Philippe
France
-
Individualised approach to managing naive patients
Presentation
-
MCHUTCHISON John
USA
-
Genetic markers: a major step for individualised care
Presentation
-
MOUCARI Rami
United Arab Emirates
-
HBsAg: clinical relevance
Presentation
-
-
Naive patients
Presentation
-
-
Management of Hepatocellular Carcinoma (chairman)
-
Hepatocellular carcinoma. Asian vs European experience
Presentation
-
-
Why do I treat my patient with a nucleos(t)ide analogue?
Presentation
-
PETERS Marion
USA
-
How to manage patients with resistant HBV (chairman)
-
Clinical case: cirrhosis with lamivudine resistance
Presentation
-
-
The role of HBsAg quantifi cation vs HBV DNA in clinical management of Hepatitis B
Presentation
-
-
HIV co-infection: does it make a difference?
Presentation
-
RAYMOND Eric
France
-
Novel molecular therapy
Presentation
-
-
Special populations (chairman)
Presentation
-
-
Difficulties faced in severe reactivation
Presentation
-
-
State of the Art lecture
Presentation
-
-
Clinical case: management of a non responder
Presentation
-
SERFATY Lawrence
France
-
How to manage patients with resistant HBV
Presentation
-
-
Is ribavirin still useful?
Presentation
-
-
French speaking luncheon: Comment optimiser la prise en charge des patients AgHBe négatif? (chairman)
Presentation
-
VALLA Dominique
France
-
Management of Hepatocellular Carcinoma (chairman)
Presentation
-
-
French speaking luncheon: Comment optimiser la prise en charge des patients AgHBe négatif?
Presentation
-
WEDEMEYER Heiner
Germany
-
Hepatitis delta reviva
Presentation
-
YURDAYDIN Cihan
Turkey
-
Special populations (chairman)
Presentation
-
-
Active or inactive carrier: where is the frontier?
Presentation
-
ZEUZEM Stefan
Germany
-
Optimal use of virological tools
-
Triple therapy: who and how? (chairman)
Presentation
-
ZOULIM Fabien
France
-
Is resistance disappearing?
Presentation
-
